In vitro anti-protozoal activity of ferrocenyl-chalcones-isatin conjugates on Trichomonas vaginalis
Poster Number
4
Format
Poster Presentation
Faculty Mentor Name
Kirkwood Land
Faculty Mentor Department
Biological Sciences
Abstract/Artist Statement
Trichomoniasis, caused by Trichomonas vaginalis, is the most common sexually transmitted disease with millions of cases occurring over the world each year. Generally, trichomoniasis is treatable by using metronidazole or tinidazole, which are the only treatments that are FDA approved. Due to the reliance on metronidazole as treatment for the disease, there are now new resistant strains of T. vaginalis on which the drug is ineffective; therefore prompting the development of other forms of drugs. The ferrocenyl-chalcones-isatin conjugates have been synthesized to test on T. vaginalis as an alternative drug for trichomoniasis. Previously, the separate components of the conjugates were tested on human subjects. They have exhibited tolerance to humans making it a possible drug derivative. Furthermore, they were found to display antimicrobial properties, which make promising derivatives. We are analyzing the effectiveness of the ferrocenyl-chalcones-isatin conjugates on the G3 strain of T. vaginalis. In preliminary testing, we found that most of the conjugate compounds are potent in inhibiting T. vaginalis growth. The IC50 values that ranged less than 10μM functioned the best at the highest concentration of 100μM. Compounds 3 and 4 of the ferrocenyl-chalcones-isatin library are found to be potent at inhibiting T. vaginalis growth with IC50 values of 5.639μM and 5.823μM.
Location
DeRosa University Center, Ballroom
Start Date
30-4-2016 10:00 AM
End Date
30-4-2016 12:00 PM
In vitro anti-protozoal activity of ferrocenyl-chalcones-isatin conjugates on Trichomonas vaginalis
DeRosa University Center, Ballroom
Trichomoniasis, caused by Trichomonas vaginalis, is the most common sexually transmitted disease with millions of cases occurring over the world each year. Generally, trichomoniasis is treatable by using metronidazole or tinidazole, which are the only treatments that are FDA approved. Due to the reliance on metronidazole as treatment for the disease, there are now new resistant strains of T. vaginalis on which the drug is ineffective; therefore prompting the development of other forms of drugs. The ferrocenyl-chalcones-isatin conjugates have been synthesized to test on T. vaginalis as an alternative drug for trichomoniasis. Previously, the separate components of the conjugates were tested on human subjects. They have exhibited tolerance to humans making it a possible drug derivative. Furthermore, they were found to display antimicrobial properties, which make promising derivatives. We are analyzing the effectiveness of the ferrocenyl-chalcones-isatin conjugates on the G3 strain of T. vaginalis. In preliminary testing, we found that most of the conjugate compounds are potent in inhibiting T. vaginalis growth. The IC50 values that ranged less than 10μM functioned the best at the highest concentration of 100μM. Compounds 3 and 4 of the ferrocenyl-chalcones-isatin library are found to be potent at inhibiting T. vaginalis growth with IC50 values of 5.639μM and 5.823μM.